|
G |
Cd1d1 |
CD1d1 molecule |
increases expression |
ISO |
Adapalene results in increased expression of CD1D protein |
CTD |
PMID:17518990 |
|
NCBI chr 2:172,423,582...172,427,089
Ensembl chr 2:172,423,582...172,427,089
|
|
G |
Crabp2 |
cellular retinoic acid binding protein 2 |
increases expression |
ISO |
Adapalene results in increased expression of CRABP2 mRNA |
CTD |
PMID:8396608 PMID:9990415 |
|
NCBI chr 2:173,417,004...173,421,352
Ensembl chr 2:173,416,857...173,421,379
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
Adapalene results in decreased expression of IL10 protein |
CTD |
PMID:17518990 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Rarg |
retinoic acid receptor, gamma |
affects response to substance |
ISO |
RARG protein affects the susceptibility to Adapalene |
CTD |
PMID:9990413 |
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Adapalene inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Tlr2 |
toll-like receptor 2 |
decreases expression |
ISO |
Adapalene results in decreased expression of TLR2 protein |
CTD |
PMID:17518990 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
|
G |
Ar |
androgen receptor |
increases activity |
ISO |
alsterpaullone analog results in increased activity of AR protein |
CTD |
PMID:21111724 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
alsterpaullone inhibits the reaction [Colchicine results in increased activity of CASP3 protein] |
CTD |
PMID:20300959 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
alsterpaullone results in decreased activity of CDK2 protein |
CTD |
PMID:12534346 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases activity |
ISO |
alsterpaullone results in decreased activity of GSK3B protein |
CTD |
PMID:12534346 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
increases expression |
ISO |
alsterpaullone results in increased expression of KLK3 mRNA |
CTD |
PMID:21111724 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
alsterpaullone results in decreased activity of LCK protein |
CTD |
PMID:12534346 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Tp53 |
tumor protein p53 |
affects localization multiple interactions |
ISO |
alsterpaullone affects the localization of TP53 protein alsterpaullone results in decreased degradation of and results in increased expression of TP53 protein |
CTD |
PMID:16055726 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein |
CTD |
PMID:15039284 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases localization |
ISO |
alvocidib results in increased localization of AIFM1 protein |
CTD |
PMID:12734434 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form |
CTD |
PMID:15039284 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with alvocidib] results in decreased expression of BAD protein |
CTD |
PMID:12231544 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bag1 |
BAG cochaperone 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of BAG1 mRNA; alvocidib results in decreased expression of BAG1 protein; alvocidib results in decreased expression of BAG1 protein alternative form |
CTD |
PMID:10887097 PMID:15972445 |
|
NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects localization increases cleavage increases expression multiple interactions |
ISO |
alvocidib affects the localization of BAX protein alvocidib results in increased cleavage of BAX protein alvocidib results in increased expression of BAX protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of BAX protein; [alvocidib co-treated with Gemcitabine] results in increased expression of BAX protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein; Epothilones promotes the reaction [alvocidib affects the localization of BAX protein] |
CTD |
PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:15770523 PMID:16951203 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression decreases response to substance multiple interactions increases expression |
ISO |
alvocidib results in decreased expression of BCL2 mRNA; alvocidib results in decreased expression of BCL2 protein BCL2 protein mutant form results in decreased susceptibility to alvocidib; BCL2 protein results in decreased susceptibility to alvocidib [alvocidib co-treated with Gemcitabine] results in decreased expression of BCL2 protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein]; BCL2 protein results in decreased susceptibility to [alvocidib co-treated with Epothilones] alvocidib results in increased expression of BCL2 |
CTD |
PMID:10887097 PMID:10995888 PMID:12170773 PMID:12517783 PMID:12589031 PMID:12734434 PMID:15770523 PMID:15972445 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of BCL2L1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BCL2L1 protein] alvocidib results in decreased expression of BCL2L1; alvocidib results in decreased expression of BCL2L1 mRNA; alvocidib results in decreased expression of BCL2L1 protein |
CTD |
PMID:12517783 PMID:15039284 PMID:15634644 PMID:16820931 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of BID protein; [alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of BID protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of BID protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of BID protein] |
CTD |
PMID:11464216 PMID:12170773 PMID:12231544 PMID:15634644 PMID:16951203 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression multiple interactions |
ISO |
alvocidib results in decreased expression of BIRC3 mRNA; alvocidib results in decreased expression of BIRC3 protein Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of BIRC3 protein] |
CTD |
PMID:12517783 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in decreased expression of BIRC5 protein; [alvocidib co-treated with PBOX-6] results in decreased expression of BIRC5 protein; alvocidib inhibits the reaction [Doxorubicin results in increased expression of and results in increased phosphorylation of BIRC5 protein]; alvocidib results in decreased phosphorylation of and results in decreased expression of BIRC5 protein alvocidib results in decreased expression of BIRC5; alvocidib results in decreased expression of BIRC5 mRNA; alvocidib results in decreased expression of BIRC5 protein |
CTD |
PMID:12517783 PMID:12517802 PMID:16012789 PMID:16820931 PMID:20206141 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
alvocidib results in increased expression of BTG2 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp3 |
caspase 3 |
affects cleavage multiple interactions increases cleavage increases activity |
ISO EXP |
alvocidib affects the cleavage of CASP3 protein alvocidib inhibits the reaction [Colchicine results in increased activity of CASP3 protein] alvocidib results in increased cleavage of CASP3 protein alvocidib results in increased activity of CASP3 protein [alvocidib co-treated with 7-hydroxystaurosporine] results in increased activity of CASP3 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP3 protein; [alvocidib co-treated with Gemcitabine] results in increased cleavage of CASP3 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP3 protein; [Irinotecan co-treated with alvocidib] results in increased activity of CASP3 protein; alvocidib affects the cleavage of and results in increased activity of CASP3 protein; alvocidib promotes the reaction [Paclitaxel results in increased activity of CASP3 protein]; alvocidib promotes the reaction [romidepsin results in increased activity of CASP3 protein]; alvocidib results in increased cleavage of and results in increased activity of CASP3 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP3 protein]; Boc-D-FMK inhibits the reaction [alvocidib results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:9808574 PMID:10430095 PMID:10896673 PMID:11482875 PMID:11751522 PMID:12170773 PMID:12231544 PMID:12517783 PMID:12589031 PMID:12941380 PMID:14555534 PMID:15014036 PMID:15634644 PMID:15770523 PMID:16012789 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of CASP8 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Imatinib Mesylate co-treated with alvocidib] results in increased activity of CASP8 protein alvocidib results in increased cleavage of CASP8 protein |
CTD |
PMID:10896673 PMID:12231544 PMID:12589031 PMID:15634644 PMID:16012789 PMID:16951203 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
affects cleavage increases activity multiple interactions |
ISO |
alvocidib affects the cleavage of CASP9 protein alvocidib results in increased activity of CASP9 protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of CASP9 protein; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased activity of CASP9 protein] |
CTD |
PMID:10896673 PMID:12170773 PMID:15634644 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cbr3 |
carbonyl reductase 3 |
decreases expression |
ISO |
alvocidib results in decreased expression of CBR3 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
alvocidib results in decreased expression of and results in decreased activity of CCNA2 protein |
CTD |
PMID:16731754 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with PBOX-6] results in decreased expression of CCNB1 protein; alvocidib inhibits the reaction [Paclitaxel results in increased expression of CCNB1 protein]; alvocidib results in decreased expression of and results in decreased activity of CCNB1 protein alvocidib results in decreased expression of CCNB1 protein |
CTD |
PMID:10430095 PMID:12517783 PMID:15014036 PMID:16731754 PMID:20206141 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of CCND1 protein alvocidib results in decreased expression of CCND1 protein alvocidib results in decreased activity of CCND1 protein |
CTD |
PMID:9802881 PMID:9829756 PMID:10441105 PMID:12517783 PMID:12589031 PMID:12734434 PMID:15634644 PMID:16905211 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
alvocidib results in decreased expression of CCNE1 protein |
CTD |
PMID:15014036 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions decreases expression decreases activity |
ISO |
[alvocidib co-treated with PBOX-6] results in decreased activity of CDK1 protein alvocidib results in decreased expression of CDK1 protein modified form alvocidib results in decreased activity of CDK1 protein |
CTD |
PMID:9427698 PMID:9802881 PMID:12517783 PMID:16905211 PMID:20206141 PMID:24102143 More...
|
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression decreases activity multiple interactions |
ISO |
alvocidib results in decreased expression of CDK2 protein modified form alvocidib results in decreased activity of CDK2 protein alvocidib binds to and results in decreased activity of CDK2 protein; alvocidib inhibits the reaction [Paclitaxel results in increased activity of CDK2 protein] |
CTD |
PMID:9802881 PMID:10430095 PMID:12517783 PMID:16905211 PMID:24102143 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases activity multiple interactions decreases expression |
ISO |
alvocidib results in decreased activity of CDK4 protein alvocidib binds to and results in decreased activity of CDK4 protein alvocidib results in decreased expression of CDK4 protein |
CTD |
PMID:12517783 PMID:12734434 PMID:24102143 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
multiple interactions |
EXP |
alvocidib inhibits the reaction [Colchicine results in increased expression of CDK5 protein] |
CTD |
PMID:12941380 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
ISO |
alvocidib binds to and results in decreased activity of CDK9 protein |
CTD |
PMID:24102143 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions decreases expression increases cleavage increases expression affects expression |
ISO |
[alvocidib co-treated with Gemcitabine] results in increased expression of CDKN1A protein; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A promoter]; alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]; Phorbol 12,13-Dibutyrate inhibits the reaction [alvocidib inhibits the reaction [romidepsin results in increased expression of CDKN1A protein]] alvocidib results in decreased expression of CDKN1A protein alvocidib results in increased cleavage of CDKN1A protein alvocidib results in increased expression of CDKN1A protein alvocidib affects the expression of CDKN1A protein |
CTD |
PMID:10537362 PMID:12734434 PMID:15014036 PMID:15180955 PMID:15770523 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases cleavage increases expression |
ISO |
alvocidib results in increased cleavage of CDKN1B protein [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of CDKN1B protein |
CTD |
PMID:10537362 PMID:12589031 PMID:15180955 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
affects expression multiple interactions decreases expression |
ISO |
alvocidib affects the expression of CFLAR mRNA benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [alvocidib results in decreased expression of CFLAR protein] alvocidib results in decreased expression of CFLAR; alvocidib results in decreased expression of CFLAR protein |
CTD |
PMID:16820931 PMID:16951203 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein |
CTD |
PMID:15039284 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
alvocidib affects the localization of CYCS protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of CYCS protein; BCL2 protein mutant form inhibits the reaction [alvocidib affects the localization of CYCS protein] |
CTD |
PMID:12170773 PMID:12517783 PMID:15634644 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein] |
CTD |
PMID:37515497 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions |
ISO |
alvocidib affects the localization of DIABLO protein [alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] affects the localization of DIABLO protein; [Imatinib Mesylate co-treated with alvocidib] results in increased secretion of DIABLO protein |
CTD |
PMID:12231544 PMID:12517783 PMID:15039284 PMID:15634644 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression increases response to substance decreases expression |
ISO |
alvocidib results in increased expression of E2F1 protein E2F1 results in increased susceptibility to alvocidib alvocidib results in decreased expression of E2F1 mRNA |
CTD |
PMID:12533675 PMID:21239698 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
H2ax |
H2A.X variant histone |
affects expression multiple interactions |
ISO |
alvocidib affects the expression of H2AX protein alvocidib inhibits the reaction [Benzo(a)pyrene results in increased expression of H2AX protein] |
CTD |
PMID:15078984 PMID:37515497 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of HMGA1 mRNA |
CTD |
PMID:21239698 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Htra2 |
HtrA serine peptidase 2 |
affects localization |
ISO |
alvocidib affects the localization of HTRA2 protein |
CTD |
PMID:12517783 |
|
NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] |
CTD |
PMID:23589332 |
|
NCBI chr 5:103,020,758...103,021,595
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Isg15 |
ISG15 ubiquitin-like modifier |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein results in increased expression of ISG15 mRNA] |
CTD |
PMID:23589332 |
|
NCBI chr 5:166,784,148...166,785,435
Ensembl chr 5:166,784,148...166,785,435
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Imatinib Mesylate co-treated with alvocidib] results in increased activity of JUN protein |
CTD |
PMID:12231544 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression decreases phosphorylation |
ISO |
alvocidib results in decreased expression of KIT mRNA; alvocidib results in decreased expression of KIT promoter alvocidib results in decreased phosphorylation of KIT protein |
CTD |
PMID:16740725 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Lyn |
LYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein |
CTD |
PMID:15039284 |
|
NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
multiple interactions |
ISO |
alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein] |
CTD |
PMID:15039284 |
|
NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:15014036 PMID:15039284 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK14 protein |
CTD |
PMID:15634644 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; alvocidib results in decreased activity of and results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:15014036 PMID:15039284 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased phosphorylation of and results in increased activity of MAPK8 protein; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein] |
CTD |
PMID:15039284 PMID:15634644 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
affects expression decreases response to substance decreases expression multiple interactions |
ISO |
alvocidib affects the expression of MCL1 mRNA; alvocidib affects the expression of MCL1 protein MCL1 results in decreased susceptibility to alvocidib alvocidib results in decreased expression of MCL1 mRNA; alvocidib results in decreased expression of MCL1 protein [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in decreased expression of MCL1 protein; [Imatinib Mesylate co-treated with alvocidib] results in decreased expression of MCL1 protein; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of MCL1 protein] |
CTD |
PMID:10887097 PMID:12231544 PMID:12429644 PMID:12517783 PMID:12533675 PMID:15634644 PMID:15972445 More...
|
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
alvocidib results in decreased expression of MDM2 mRNA; alvocidib results in decreased expression of MDM2 protein |
CTD |
PMID:12589031 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mx1 |
MX dynamin like GTPase 1 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr11:36,799,659...36,825,209
Ensembl chr11:36,799,660...36,823,507
|
|
G |
Nelfa |
negative elongation factor complex member A |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [NELFA protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr14:76,808,920...76,832,998
Ensembl chr14:76,808,870...76,832,994
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions |
ISO |
alvocidib results in increased expression of NFKBIA protein modified form alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form] |
CTD |
PMID:15039284 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
alvocidib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[alvocidib co-treated with 7-hydroxystaurosporine] results in increased cleavage of PARP1 protein; [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [alvocidib co-treated with ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate] results in increased cleavage of PARP1 protein; [alvocidib co-treated with Gemcitabine] results in increased cleavage of PARP1 protein; alvocidib promotes the reaction [Paclitaxel results in increased cleavage of PARP1 protein]; BCL2 protein mutant form inhibits the reaction [alvocidib results in increased cleavage of PARP1 protein] |
CTD |
PMID:10430095 PMID:12170773 PMID:12517783 PMID:15039284 PMID:15634644 PMID:15770523 PMID:15972445 PMID:16012789 PMID:20663931 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pawr |
pro-apoptotic WT1 regulator |
multiple interactions |
EXP |
alvocidib inhibits the reaction [Colchicine results in increased expression of PAWR protein] |
CTD |
PMID:12941380 |
|
NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases activity |
ISO |
alvocidib results in decreased activity of PCNA protein |
CTD |
PMID:10441105 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Perp |
p53 apoptosis effector related to PMP22 |
increases expression |
ISO |
alvocidib results in increased expression of PERP mRNA |
CTD |
PMID:21382384 |
|
NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511
|
|
G |
Polr2a |
RNA polymerase II subunit A |
decreases expression decreases phosphorylation multiple interactions |
ISO |
alvocidib results in decreased expression of POLR2A mRNA alvocidib results in decreased phosphorylation of POLR2A protein Bortezomib promotes the reaction [alvocidib results in decreased phosphorylation of POLR2A protein] alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 gene]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [POLR2A protein binds to ISG15 promoter]] |
CTD |
PMID:15039284 PMID:21239698 PMID:23589332 PMID:24102143 |
|
NCBI chr10:54,452,438...54,478,486
Ensembl chr10:54,452,441...54,478,455
|
|
G |
Pygb |
glycogen phosphorylase B |
affects binding |
ISO |
PYGB protein binds to alvocidib |
CTD |
PMID:11368340 |
|
NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
|
|
G |
Pygl |
glycogen phosphorylase L |
affects binding |
ISO |
PYGL protein binds to alvocidib |
CTD |
PMID:11368340 |
|
NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases activity decreases response to substance multiple interactions decreases phosphorylation decreases expression |
ISO |
alvocidib results in decreased activity of RB1 protein modified form RB1 results in decreased susceptibility to alvocidib [docetaxel co-treated with alvocidib] results in decreased phosphorylation of and results in decreased expression of RB1 protein alvocidib results in decreased phosphorylation of RB1 protein alvocidib results in decreased expression of RB1 protein; alvocidib results in decreased expression of RB1 protein modified form |
CTD |
PMID:9829756 PMID:10441105 PMID:15180955 PMID:15297405 PMID:16905211 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
alvocidib results in decreased expression of RBL1 protein |
CTD |
PMID:9829756 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions decreases expression |
ISO |
[alvocidib co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased activity of STAT3 protein alvocidib results in decreased expression of STAT3 mRNA |
CTD |
PMID:15039284 PMID:21239698 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Supt5h |
SPT5 homolog, DSIF elongation factor subunit |
multiple interactions |
ISO |
alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to IFIT1 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to ISG15 promoter]]; alvocidib inhibits the reaction [IFNB1 protein promotes the reaction [SUPT5H protein binds to MX1 promoter]] |
CTD |
PMID:23589332 |
|
NCBI chr 1:83,586,713...83,616,971
Ensembl chr 1:83,586,718...83,616,892
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases activity |
ISO |
alvocidib analog results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
alvocidib inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:21204955 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
alvocidib results in increased expression of TNFRSF10A |
CTD |
PMID:16820931 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions increases response to substance increases expression |
ISO |
[alvocidib co-treated with TNFSF10 protein] results in decreased expression of BID protein; [alvocidib co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [alvocidib co-treated with TNFSF10 protein] results in increased localization of BAX protein alvocidib results in increased susceptibility to TNFSF10 alvocidib results in increased expression of TNFSF10 |
CTD |
PMID:16820931 PMID:16951203 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression multiple interactions increases expression |
ISO |
alvocidib results in decreased expression of TP53 protein [docetaxel co-treated with alvocidib] results in increased expression of TP53 protein [alvocidib results in increased expression of TP53 protein] which results in increased expression of CDKN1B protein; alvocidib results in increased expression of TP53 protein |
CTD |
PMID:9808574 PMID:10537362 PMID:12589031 PMID:15180955 PMID:15297405 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
alvocidib results in decreased expression of VEGFA mRNA |
CTD |
PMID:21239698 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression multiple interactions |
ISO |
alvocidib results in decreased expression of XIAP mRNA; alvocidib results in decreased expression of XIAP protein [irinotecan co-treated with alvocidib] results in increased cleavage of XIAP protein; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP mRNA]; Epothilones promotes the reaction [alvocidib results in decreased expression of XIAP protein] |
CTD |
PMID:10887097 PMID:11751522 PMID:12517783 PMID:15385934 PMID:15972445 PMID:16951203 More...
|
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
bohemine results in decreased activity of CDK2 protein |
CTD |
PMID:15026556 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
dinaciclib binds to and results in decreased activity of AKR1C3 protein; dinaciclib inhibits the reaction [AKR1C3 protein results in decreased susceptibility to Daunorubicin] |
CTD |
PMID:29992508 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression |
ISO |
dinaciclib results in decreased expression of BRCA1 mRNA; dinaciclib results in decreased expression of BRCA1 protein |
CTD |
PMID:27880910 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression |
ISO |
dinaciclib results in decreased expression of BRCA2 protein |
CTD |
PMID:27880910 |
|
NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[dinaciclib results in increased susceptibility to Doxorubicin] which results in increased cleavage of CASP3 protein; dinaciclib promotes the reaction [Doxorubicin results in increased cleavage of CASP3 protein] |
CTD |
PMID:27378523 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccna1 |
cyclin A1 |
decreases expression |
ISO |
dinaciclib results in decreased expression of CCNA1 protein |
CTD |
PMID:38135130 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
dinaciclib results in decreased expression of CCND1 protein |
CTD |
PMID:38135130 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
dinaciclib results in decreased expression of CDK1 protein |
CTD |
PMID:38135130 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk12 |
cyclin-dependent kinase 12 |
decreases activity |
ISO |
dinaciclib results in decreased activity of CDK12 protein |
CTD |
PMID:27880910 |
|
NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888 Ensembl chr10:83,201,211...83,280,888
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
dinaciclib results in decreased activity of CDK2 protein |
CTD |
PMID:27378523 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
dinaciclib results in decreased expression of CDK4 protein |
CTD |
PMID:38135130 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
dinaciclib results in decreased expression of CDK6 protein |
CTD |
PMID:38135130 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
decreases activity |
ISO |
dinaciclib results in decreased activity of CDK9 protein |
CTD |
PMID:27378523 PMID:27880910 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases expression |
ISO |
dinaciclib results in decreased expression of FANCD2 protein |
CTD |
PMID:27880910 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
affects phosphorylation |
ISO |
dinaciclib affects the phosphorylation of MAPK1 protein |
CTD |
PMID:38135130 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
affects phosphorylation |
ISO |
dinaciclib affects the phosphorylation of MAPK3 protein |
CTD |
PMID:38135130 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
affects expression |
ISO |
dinaciclib affects the expression of MYC protein |
CTD |
PMID:38135130 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
dinaciclib results in increased cleavage of PARP1 protein [dinaciclib results in increased susceptibility to Doxorubicin] which results in increased cleavage of PARP1 protein; dinaciclib promotes the reaction [Doxorubicin results in increased cleavage of PARP1 protein] |
CTD |
PMID:20663931 PMID:27378523 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
dinaciclib results in decreased expression of RAD51 protein |
CTD |
PMID:27880910 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
dinaciclib results in decreased phosphorylation of RB1 protein |
CTD |
PMID:20663931 PMID:27378523 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
dinaciclib results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:38135130 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
|
G |
Actb |
actin, beta |
affects expression |
ISO |
indirubin-3'-monoxime affects the expression of ACTB protein |
CTD |
PMID:18958680 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects binding |
ISO |
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein] indirubin-3'-monoxime binds to and results in increased activity of AHR protein indirubin-3'-monoxime binds to AHR protein |
CTD |
PMID:15001395 PMID:21948866 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of ALDH1A1 protein] |
CTD |
PMID:21948866 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
decreases expression |
ISO |
indirubin-3'-monoxime results in decreased expression of ALDH1A2 protein |
CTD |
PMID:21948866 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 mRNA]; indirubin-3'-monoxime promotes the reaction [tetraarsenic tetrasulfide results in increased expression of AQP9 protein] |
CTD |
PMID:18344322 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
increases activity |
ISO |
indirubin-3'-monoxime analog results in increased activity of AR protein; indirubin-3'-monoxime results in increased activity of AR protein |
CTD |
PMID:21111724 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
indirubin-3'-monoxime results in decreased expression of BAX mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CASP8 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CAT mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of CCL4 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions decreases expression |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD40 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein] indirubin-3'-monoxime results in decreased expression of CD40 protein |
CTD |
PMID:21948866 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd80 |
Cd80 molecule |
increases expression multiple interactions |
ISO |
indirubin-3'-monoxime results in increased expression of CD80 protein [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased expression of CD80 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased expression of CD80 protein] |
CTD |
PMID:21948866 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions decreases expression |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of CD86 protein; AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of CD86 protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein] |
CTD |
PMID:21948866 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
indirubin-3'-monoxime results in decreased activity of CDK2 protein |
CTD |
PMID:12534346 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CDKN1A mRNA |
CTD |
PMID:18958680 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO EXP |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP1A1 protein indirubin-3'-monoxime results in increased expression of CYP1A1 mRNA indirubin-3'-monoxime results in increased expression of CYP1A1 protein |
CTD |
PMID:15001395 PMID:18958680 PMID:21948866 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO |
indirubin-3'-monoxime results in decreased expression of EPHX2 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
indirubin-3'-monoxime results in decreased expression of GPX1 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases activity |
ISO |
indirubin-3'-monoxime results in decreased activity of GSK3B protein |
CTD |
PMID:12534346 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
indirubin-3'-monoxime results in increased expression of GSR mRNA |
CTD |
PMID:18958680 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HMOX1 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of HSPA2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA2 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 6:95,128,504...95,131,281
Ensembl chr 6:95,128,350...95,131,287
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA6 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Hspa9 |
heat shock protein family A (Hsp70) member 9 |
multiple interactions increases expression |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of HSPA9 mRNA indirubin-3'-monoxime results in increased expression of HSPA9 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases expression |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of ICAM1 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] indirubin-3'-monoxime results in decreased expression of ICAM1 protein |
CTD |
PMID:21948866 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression multiple interactions |
ISO |
indirubin-3'-monoxime results in increased expression of IDO1 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO1 protein] |
CTD |
PMID:21948866 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ido2 |
indoleamine 2,3-dioxygenase 2 |
increases expression multiple interactions |
ISO |
indirubin-3'-monoxime results in increased expression of IDO2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of IDO2 protein] |
CTD |
PMID:21948866 |
|
NCBI chr16:67,459,158...67,498,052
Ensembl chr16:67,459,190...67,496,324
|
|
G |
Ifng |
interferon gamma |
decreases secretion |
ISO |
indirubin-3'-monoxime results in decreased secretion of IFNG protein |
CTD |
PMID:21948866 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions decreases secretion |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased secretion of IL10 protein; indirubin-3'-monoxime promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] indirubin-3'-monoxime results in decreased secretion of IL10 protein |
CTD |
PMID:21948866 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL1B protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:21948866 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases secretion |
ISO |
indirubin-3'-monoxime results in increased secretion of IL2 protein |
CTD |
PMID:21948866 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il27 |
interleukin 27 |
decreases expression multiple interactions |
ISO |
indirubin-3'-monoxime results in decreased expression of IL27 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of IL27 protein] |
CTD |
PMID:21948866 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased expression of IL6 protein; [Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of IL6 protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] |
CTD |
PMID:21948866 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgax |
integrin subunit alpha X |
multiple interactions decreases expression |
ISO |
AHR protein affects the susceptibility to [indirubin-3'-monoxime results in decreased expression of ITGAX protein]; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAX protein] |
CTD |
PMID:21948866 |
|
NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
increases expression |
ISO |
indirubin-3'-monoxime analog results in increased expression of KLK3 mRNA; indirubin-3'-monoxime results in increased expression of KLK3 mRNA |
CTD |
PMID:21111724 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
indirubin-3'-monoxime results in decreased activity of LCK protein |
CTD |
PMID:12534346 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of MT2A mRNA |
CTD |
PMID:18958680 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate co-treated with Lipopolysaccharides] results in decreased expression of NFKBIA mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 mRNA; [indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PTGS2 protein |
CTD |
PMID:18958680 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
indirubin-3'-monoxime results in decreased expression of RAD23A mRNA |
CTD |
PMID:18958680 |
|
NCBI chr19:23,313,563...23,320,702
Ensembl chr19:23,314,797...23,320,695
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in increased activity of RELA protein indirubin-3'-monoxime results in decreased activity of RELA protein |
CTD |
PMID:21948866 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
decreases activity |
ISO |
indirubin-3'-monoxime results in decreased activity of SGK1 protein |
CTD |
PMID:12534346 |
|
NCBI chr 1:22,980,257...23,098,122
Ensembl chr 1:22,980,261...23,098,283
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[indirubin-3'-monoxime co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of SOD2 mRNA |
CTD |
PMID:18958680 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression multiple interactions |
ISO |
indirubin-3'-monoxime results in increased expression of TGFB2 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB2 protein] |
CTD |
PMID:21948866 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
increases expression multiple interactions |
ISO |
indirubin-3'-monoxime results in increased expression of TGFB3 protein Lipopolysaccharides affects the susceptibility to [indirubin-3'-monoxime results in increased expression of TGFB3 protein] |
CTD |
PMID:21948866 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with indirubin-3'-monoxime] results in decreased secretion of TNF protein; indirubin-3'-monoxime inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:21948866 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ung |
uracil-DNA glycosylase |
increases expression |
ISO |
indirubin-3'-monoxime results in increased expression of UNG mRNA |
CTD |
PMID:18958680 |
|
NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
kenpaullone results in increased expression of ABCB1 protein |
CTD |
PMID:18624906 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Adm |
adrenomedullin |
decreases expression |
EXP |
kenpaullone results in decreased expression of ADM mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Ar |
androgen receptor |
affects localization increases activity |
ISO |
kenpaullone analog affects the localization of AR protein kenpaullone analog results in increased activity of AR protein |
CTD |
PMID:21111724 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
kenpaullone inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form] |
CTD |
PMID:25633564 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
increases expression |
ISO |
kenpaullone results in increased expression of BMPR2 mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
kenpaullone inhibits the reaction [fipronil results in increased activity of CASP3 protein] |
CTD |
PMID:21296133 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
EXP |
kenpaullone results in decreased expression of CCNG2 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity |
ISO |
kenpaullone results in decreased activity of CDK2 protein |
CTD |
PMID:12534346 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cited2 |
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
decreases expression |
EXP |
kenpaullone results in decreased expression of CITED2 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization |
ISO |
kenpaullone analog affects the localization of CTNNB1 protein |
CTD |
PMID:21111724 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
decreases expression |
EXP |
kenpaullone results in decreased expression of DDIT4 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
decreases expression |
EXP |
kenpaullone results in decreased expression of DUSP1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
decreases expression |
EXP |
kenpaullone results in decreased expression of ERRFI1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Exo1 |
exonuclease 1 |
decreases expression |
EXP |
kenpaullone results in decreased expression of EXO1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
kenpaullone results in increased expression of FOS mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
kenpaullone results in increased expression of FOSB mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Furin |
furin (paired basic amino acid cleaving enzyme) |
decreases expression |
ISO |
kenpaullone results in decreased expression of FURIN mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:134,348,142...134,361,182
Ensembl chr 1:134,348,144...134,364,314
|
|
G |
Fzd8 |
frizzled class receptor 8 |
decreases expression |
EXP |
kenpaullone results in decreased expression of FZD8 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
decreases expression |
EXP |
kenpaullone results in decreased expression of GADD45B mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Giot1 |
gonadotropin inducible ovarian transcription factor 1 |
decreases expression |
EXP |
kenpaullone results in decreased expression of GIOT1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 7:10,215,602...10,236,423
Ensembl chr 7:10,202,982...10,237,099
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
decreases phosphorylation |
EXP |
kenpaullone results in decreased phosphorylation of GSK3A protein |
CTD |
PMID:17993264 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases activity decreases phosphorylation |
ISO EXP |
kenpaullone inhibits the reaction [fipronil results in decreased phosphorylation of GSK3B protein] kenpaullone results in decreased activity of GSK3B protein kenpaullone results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:12534346 PMID:17993264 PMID:21111724 PMID:21296133 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression decreases secretion multiple interactions |
ISO |
kenpaullone results in decreased expression of HAMP mRNA kenpaullone results in decreased secretion of HAMP protein modified form kenpaullone inhibits the reaction [BMP6 protein results in increased secretion of HAMP protein modified form]; kenpaullone inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hoxa1 |
homeobox A1 |
increases expression |
ISO |
kenpaullone results in increased expression of HOXA1 |
CTD |
PMID:26820057 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
kenpaullone inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Isl2 |
ISL LIM homeobox 2 |
increases expression |
EXP |
kenpaullone results in increased expression of ISL2 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 8:55,923,805...55,928,790
Ensembl chr 8:55,923,805...55,928,790
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
kenpaullone results in increased expression of JUNB protein |
CTD |
PMID:17993264 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Klf6 |
KLF transcription factor 6 |
decreases expression |
EXP |
kenpaullone results in decreased expression of KLF6 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
increases expression |
ISO |
kenpaullone results in increased expression of KLK3 mRNA |
CTD |
PMID:21111724 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
kenpaullone results in decreased activity of LCK protein |
CTD |
PMID:12534346 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases expression |
EXP |
kenpaullone results in increased expression of LIF mRNA |
CTD |
PMID:17993264 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Mex3b |
mex-3 RNA binding family member B |
decreases expression |
EXP |
kenpaullone results in decreased expression of MEX3B mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 1:136,855,130...136,859,365
Ensembl chr 1:136,855,130...136,859,354
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
kenpaullone promotes the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:25341891 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
EXP |
kenpaullone results in increased expression of NR4A1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
decreases expression |
EXP |
kenpaullone results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pnrc1 |
proline-rich nuclear receptor coactivator 1 |
decreases expression |
EXP |
kenpaullone results in decreased expression of PNRC1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 5:47,647,070...47,657,832
Ensembl chr 5:47,647,071...47,650,161
|
|
G |
Ppp1r3b |
protein phosphatase 1, regulatory subunit 3B |
decreases expression |
EXP |
kenpaullone results in decreased expression of PPP1R3B mRNA |
CTD |
PMID:17993264 |
|
NCBI chr16:56,830,011...56,842,395
Ensembl chr16:56,829,660...56,842,406
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
decreases expression |
EXP |
kenpaullone results in decreased expression of PTGER4 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
EXP |
kenpaullone results in increased expression of PTGS2 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
decreases expression |
EXP |
kenpaullone results in decreased expression of RGS4 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
G |
Sox18 |
SRY-box transcription factor 18 |
decreases expression |
EXP |
kenpaullone results in decreased expression of SOX18 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 3:168,785,488...168,787,290
Ensembl chr 3:168,785,490...168,787,290
|
|
G |
Spry1 |
sprouty RTK signaling antagonist 1 |
decreases expression |
EXP |
kenpaullone results in decreased expression of SPRY1 mRNA |
CTD |
PMID:17993264 |
|
NCBI chr 2:120,557,256...120,561,917
Ensembl chr 2:120,556,706...120,566,189
|
|
G |
Tfr2 |
transferrin receptor 2 |
decreases expression |
ISO |
kenpaullone results in decreased expression of TFR2 mRNA |
CTD |
PMID:25633564 |
|
NCBI chr12:19,107,673...19,124,622
Ensembl chr12:19,107,673...19,124,591
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
kenpaullone results in increased expression of TFRC mRNA |
CTD |
PMID:25633564 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
EXP |
kenpaullone results in decreased expression of TNF mRNA |
CTD |
PMID:17993264 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
kenpaullone results in increased expression of TYR mRNA |
CTD |
PMID:21071833 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]]; olomoucine inhibits the reaction [TP53 results in decreased phosphorylation of CDK1 protein] |
CTD |
PMID:16628227 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity multiple interactions |
ISO EXP |
olomoucine results in decreased activity of CDK2 protein olomoucine inhibits the reaction [CDK2 protein results in increased phosphorylation of TPI1 protein] |
CTD |
PMID:12387751 PMID:15026556 PMID:20149834 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases expression |
ISO |
olomoucine results in increased expression of RB1 mRNA; olomoucine results in increased expression of RB1 protein |
CTD |
PMID:14653808 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Sp1 |
Sp1 transcription factor |
increases expression |
ISO |
olomoucine results in increased expression of SP1 mRNA; olomoucine results in increased expression of SP1 protein |
CTD |
PMID:14653808 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]]; olomoucine inhibits the reaction [TP53 results in decreased phosphorylation of CDK1 protein] |
CTD |
PMID:16628227 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
multiple interactions |
ISO |
olomoucine inhibits the reaction [CDK2 protein results in increased phosphorylation of TPI1 protein] |
CTD |
PMID:20149834 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
palbociclib results in increased expression of ABCA1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO |
BMS 754807 inhibits the reaction [palbociclib results in increased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:23676220 PMID:24986516 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Anln |
anillin, actin binding protein |
decreases expression |
ISO |
palbociclib results in decreased expression of ANLN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
ISO |
palbociclib results in increased expression of APOE mRNA |
CTD |
PMID:28620137 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression |
ISO |
palbociclib results in decreased expression of ASF1B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
palbociclib results in decreased expression of AURKA mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
palbociclib results in decreased expression of AURKB mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of BARD1 mRNA |
CTD |
PMID:22869556 PMID:28620137 |
|
NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of BIRC5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bora |
bora, aurora kinase A activator |
decreases expression |
ISO |
palbociclib results in decreased expression of BORA mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of BUB1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage decreases cleavage |
ISO |
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein] palbociclib results in increased cleavage of CASP3 protein [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein palbociclib results in decreased cleavage of CASP3 protein |
CTD |
PMID:22302033 PMID:22751436 PMID:23676220 PMID:24098593 PMID:27099147 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP7 protein] [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein |
CTD |
PMID:22302033 PMID:24098593 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
ISO |
palbociclib results in increased expression of CCN1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression multiple interactions |
ISO |
palbociclib results in decreased expression of CCNA2 mRNA; palbociclib results in decreased expression of CCNA2 protein E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein] |
CTD |
PMID:20100483 PMID:20473330 PMID:21367843 PMID:21593195 PMID:22751436 PMID:22869556 PMID:23708653 PMID:24606660 PMID:26318986 More...
|
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
palbociclib results in decreased expression of CCNB1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression |
ISO |
palbociclib results in decreased expression of CCNB2 mRNA |
CTD |
PMID:22869556 PMID:28620137 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
decreases response to substance multiple interactions increases expression |
ISO |
CCND1 gene results in decreased susceptibility to palbociclib [CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CCND1 protein [BMS 754807 co-treated with palbociclib] results in increased expression of CCND1 protein; Doxorubicin inhibits the reaction [palbociclib results in increased expression of CCND1 protein]; palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein] |
CTD |
PMID:20473330 PMID:21278246 PMID:22094256 PMID:22751436 PMID:22869556 PMID:23708653 PMID:24098593 PMID:24986516 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
ISO |
[CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib |
CTD |
PMID:24098593 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions increases expression |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein] [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CCND3 protein |
CTD |
PMID:20473330 PMID:22094256 PMID:24098593 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases response to substance decreases expression increases expression |
ISO |
CCNE1 protein results in decreased susceptibility to palbociclib palbociclib results in decreased expression of CCNE1 protein palbociclib results in increased expression of CCNE1 protein |
CTD |
PMID:17537993 PMID:21278246 PMID:21880723 PMID:23708653 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
palbociclib analog results in decreased expression of CCNE2 mRNA; palbociclib results in decreased expression of CCNE2 mRNA |
CTD |
PMID:15542782 PMID:22869556 PMID:26318986 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
palbociclib results in decreased expression of CCNF mRNA |
CTD |
PMID:22869556 PMID:24606660 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC20 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC25A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC25C mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc37 |
cell division cycle 37, HSP90 cochaperone |
multiple interactions |
ISO |
palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein] |
CTD |
PMID:29091774 |
|
NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
|
|
G |
Cdc45 |
cell division cycle 45 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDC45 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDCA3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799
|
|
G |
Cdca5 |
cell division cycle associated 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDCA5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023
|
|
G |
Cdca8 |
cell division cycle associated 8 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDCA8 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629
|
|
G |
Cdh1 |
cadherin 1 |
affects localization multiple interactions |
ISO |
palbociclib affects the localization of CDH1 protein CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein] |
CTD |
PMID:22094256 PMID:22869556 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions increases expression |
ISO |
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDH2 protein] |
CTD |
PMID:22869556 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
palbociclib analog results in decreased expression of CDK1 mRNA; palbociclib results in decreased expression of CDK1 mRNA |
CTD |
PMID:15542782 PMID:22869556 PMID:24606660 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases activity multiple interactions decreases phosphorylation decreases expression |
ISO |
palbociclib results in decreased activity of CDK2 protein palbociclib results in increased phosphorylation of and results in increased expression of CDK2 protein palbociclib results in decreased phosphorylation of CDK2 protein palbociclib results in decreased expression of CDK2 protein |
CTD |
PMID:17537993 PMID:20100483 PMID:20473330 PMID:21880723 PMID:22869556 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases response to substance decreases activity multiple interactions increases expression increases response to substance |
ISO |
CDK4 protein results in decreased susceptibility to palbociclib palbociclib results in decreased activity of CDK4 protein [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib palbociclib results in increased expression of CDK4 protein palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein] CDK4 protein results in increased susceptibility to palbociclib |
CTD |
PMID:20473330 PMID:22094256 PMID:22711607 PMID:22761470 PMID:22869556 PMID:23708653 PMID:24098593 PMID:24795392 PMID:29091774 More...
|
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions increases expression |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein] palbociclib results in increased expression of CDK6 protein [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib |
CTD |
PMID:20473330 PMID:22094256 PMID:22869556 PMID:23138228 PMID:24098593 PMID:29091774 More...
|
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
increases expression |
ISO |
palbociclib results in increased expression of CDK7 mRNA |
CTD |
PMID:24606660 |
|
NCBI chr 2:31,840,558...31,865,422
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
palbociclib results in increased expression of CDKN1A protein |
CTD |
PMID:20473330 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression decreases expression |
ISO |
palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein] palbociclib results in increased expression of CDKN1B mRNA; palbociclib results in increased expression of CDKN1B protein palbociclib results in decreased expression of CDKN1B protein |
CTD |
PMID:17537993 PMID:20473330 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
affects response to substance increases response to substance multiple interactions decreases response to substance |
ISO |
CDKN2A gene modified form affects the susceptibility to palbociclib; CDKN2A gene mutant form affects the susceptibility to palbociclib; CDKN2A protein affects the susceptibility to palbociclib CDKN2A gene mutant form results in increased susceptibility to palbociclib [CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein CDKN2A protein results in decreased susceptibility to palbociclib [CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib |
CTD |
PMID:20534551 PMID:21278246 PMID:22711607 PMID:24098593 PMID:24495407 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression multiple interactions decreases response to substance |
ISO |
palbociclib results in increased expression of CDKN2B protein 2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDKN2B protein] CDKN2B protein results in decreased susceptibility to palbociclib |
CTD |
PMID:22711607 PMID:22869556 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib |
CTD |
PMID:20534551 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDKN3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdt1 |
chromatin licensing and DNA replication factor 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of CDT1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPA mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpe |
centromere protein E |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPE mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPF mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenpm |
centromere protein M |
decreases expression |
ISO |
palbociclib results in decreased expression of CENPM mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258
|
|
G |
Cep55 |
centrosomal protein 55 |
decreases expression |
ISO |
palbociclib results in decreased expression of CEP55 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394
|
|
G |
Ckap2l |
cytoskeleton associated protein 2-like |
decreases expression |
ISO |
palbociclib results in decreased expression of CKAP2L mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366
|
|
G |
Cpa4 |
carboxypeptidase A4 |
increases expression |
ISO |
palbociclib results in increased expression of CPA4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:59,188,284...59,212,255
Ensembl chr 4:59,188,284...59,212,255
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions increases expression |
ISO |
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CTNNB1 protein] |
CTD |
PMID:22869556 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Dennd6b |
DENN domain containing 6B |
increases expression |
ISO |
palbociclib results in increased expression of DENND6B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494
|
|
G |
Depdc1b |
DEP domain containing 1B |
decreases expression |
ISO |
palbociclib results in decreased expression of DEPDC1B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779
|
|
G |
Dlgap5 |
DLG associated protein 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Donson |
DNA replication fork stabilization factor DONSON |
decreases expression |
ISO |
palbociclib results in decreased expression of DONSON mRNA |
CTD |
PMID:22869556 |
|
NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]] |
CTD |
PMID:22751436 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
multiple interactions decreases expression |
ISO |
E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased expression of RNR2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein] palbociclib results in decreased expression of E2F2 mRNA |
CTD |
PMID:20100483 PMID:20473330 PMID:22869556 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
Eln |
elastin |
increases expression |
ISO |
palbociclib results in increased expression of ELN protein |
CTD |
PMID:21880723 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Exo1 |
exonuclease 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of EXO1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
decreases expression |
ISO |
palbociclib results in decreased expression of EZH2 mRNA; palbociclib results in decreased expression of EZH2 protein |
CTD |
PMID:20948315 PMID:22869556 PMID:24736461 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
palbociclib results in increased expression of F3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fam111a |
FAM111 trypsin like peptidase A |
decreases expression |
ISO |
palbociclib results in decreased expression of FAM111A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
decreases expression |
ISO |
palbociclib results in decreased expression of FAM83D mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192
|
|
G |
Fance |
FA complementation group E |
decreases expression |
ISO |
palbociclib results in decreased expression of FANCE mRNA |
CTD |
PMID:28620137 |
|
NCBI chr20:6,369,416...6,386,631
Ensembl chr20:6,375,573...6,386,631
|
|
G |
Fanci |
FA complementation group I |
decreases expression |
ISO |
palbociclib results in decreased expression of FANCI mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fbxo5 |
F-box protein 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of FBXO5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of FEN1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Flt3 |
Fms related receptor tyrosine kinase 3 |
decreases expression affects response to substance decreases phosphorylation multiple interactions |
ISO |
palbociclib results in decreased expression of FLT3 mRNA; palbociclib results in decreased expression of FLT3 protein FLT3 protein affects the susceptibility to palbociclib palbociclib results in decreased phosphorylation of FLT3 protein [FLT3 protein affects the susceptibility to palbociclib] which results in decreased expression of FLT3 protein |
CTD |
PMID:27099147 |
|
NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of FOXM1 protein]; CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein]; palbociclib results in decreased expression of and results in decreased activity of FOXM1 protein palbociclib results in decreased expression of FOXM1 mRNA |
CTD |
PMID:22094256 PMID:22869556 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Gins2 |
GINS complex subunit 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of GINS2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339
|
|
G |
Gls |
glutaminase |
increases expression |
ISO |
palbociclib results in increased expression of GLS mRNA |
CTD |
PMID:28620137 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gmnn |
geminin, DNA replication inhibitor |
decreases expression |
ISO |
palbociclib results in decreased expression of GMNN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054
|
|
G |
Gpsm2 |
G-protein signaling modulator 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of GPSM2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
increases secretion |
ISO |
palbociclib results in increased secretion of GPT protein |
CTD |
PMID:29655783 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases phosphorylation |
ISO |
Doxorubicin inhibits the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Paclitaxel results in increased expression of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein] |
CTD |
PMID:22302033 PMID:22751436 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hjurp |
Holliday junction recognition protein |
decreases expression |
ISO |
palbociclib results in decreased expression of HJURP mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 9:88,853,379...88,867,730
Ensembl chr 9:88,853,386...88,867,728
|
|
G |
Hmgb2 |
high mobility group box 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of HMGB2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
palbociclib results in decreased expression of HMMR mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions |
ISO |
[BMS 754807 co-treated with palbociclib] results in decreased phosphorylation of IGF1R protein |
CTD |
PMID:24986516 |
|
NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il20rb |
interleukin 20 receptor subunit beta |
increases expression |
ISO |
palbociclib results in increased expression of IL20RB mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942
|
|
G |
Incenp |
inner centromere protein |
decreases expression |
ISO |
palbociclib results in decreased expression of INCENP mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265
|
|
G |
Kif11 |
kinesin family member 11 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF11 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766
|
|
G |
Kif14 |
kinesin family member 14 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF14 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164
|
|
G |
Kif15 |
kinesin family member 15 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF15 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750
|
|
G |
Kif20a |
kinesin family member 20A |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF20A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780
|
|
G |
Kif23 |
kinesin family member 23 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF23 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072
|
|
G |
Kif2c |
kinesin family member 2C |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF2C mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Kif4a |
kinesin family member 4A |
decreases expression |
ISO |
palbociclib results in decreased expression of KIF4A mRNA |
CTD |
PMID:22869556 |
|
NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139
|
|
G |
Kifc1 |
kinesin family member C1 |
decreases expression |
ISO |
palbociclib results in decreased expression of KIFC1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
multiple interactions |
ISO |
palbociclib promotes the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA] |
CTD |
PMID:23708653 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Knstrn |
kinetochore-localized astrin/SPAG5 binding protein |
decreases expression |
ISO |
palbociclib results in decreased expression of KNSTRN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715
|
|
G |
Kpna2 |
karyopherin subunit alpha 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of KPNA2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
palbociclib results in increased expression of LAMA3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
palbociclib results in increased expression of LAMB3 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
palbociclib results in increased expression of LAMC2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
palbociclib results in decreased expression of LMNB1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Mcm10 |
minichromosome maintenance 10 replication initiation factor |
decreases expression |
ISO |
palbociclib results in decreased expression of MCM10 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364
|
|
G |
Mcm7 |
minichromosome maintenance complex component 7 |
multiple interactions decreases expression |
ISO |
RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein] palbociclib results in decreased expression of MCM7 mRNA; palbociclib results in decreased expression of MCM7 protein |
CTD |
PMID:20473330 PMID:22869556 |
|
NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein] |
CTD |
PMID:22094256 |
|
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of MELK mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions decreases expression |
ISO |
Doxorubicin promotes the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein] |
CTD |
PMID:15542782 PMID:22170262 PMID:22383795 PMID:22751436 PMID:23708653 PMID:26318986 PMID:28620137 More...
|
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mxd4 |
Max dimerization protein 4 |
increases expression |
ISO |
palbociclib results in increased expression of MXD4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr14:76,562,105...76,576,224
Ensembl chr14:76,561,774...76,576,221
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
palbociclib results in decreased expression of MYC protein |
CTD |
PMID:27099147 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncapd2 |
non-SMC condensin I complex, subunit D2 |
decreases expression |
ISO |
palbociclib results in decreased expression of NCAPD2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:157,968,814...157,992,314
Ensembl chr 4:157,968,815...157,992,020
|
|
G |
Ncapg |
non-SMC condensin I complex, subunit G |
decreases expression |
ISO |
palbociclib results in decreased expression of NCAPG mRNA |
CTD |
PMID:22869556 |
|
NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902
|
|
G |
Ncapg2 |
non-SMC condensin II complex, subunit G2 |
decreases expression |
ISO |
palbociclib results in decreased expression of NCAPG2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159
|
|
G |
Ndc80 |
NDC80 kinetochore complex component |
decreases expression |
ISO |
palbociclib results in decreased expression of NDC80 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924
|
|
G |
Nek2 |
NIMA-related kinase 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of NEK2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Oip5 |
Opa interacting protein 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of OIP5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]] |
CTD |
PMID:22751436 PMID:23676220 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pbk |
PDZ binding kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of PBK mRNA |
CTD |
PMID:22869556 |
|
NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014
|
|
G |
Pclaf |
PCNA clamp associated factor |
decreases expression |
ISO |
palbociclib results in decreased expression of PCLAF mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994 Ensembl chr 8:66,420,587...66,432,994
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
ISO |
palbociclib results in decreased expression of PCNA mRNA; palbociclib results in decreased expression of PCNA protein |
CTD |
PMID:20473330 PMID:22869556 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]] |
CTD |
PMID:21880723 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Phf19 |
PHD finger protein 19 |
decreases expression |
ISO |
palbociclib results in decreased expression of PHF19 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405
|
|
G |
Pim1 |
Pim-1 proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of PIM1 mRNA |
CTD |
PMID:27099147 |
|
NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174
|
|
G |
Pimreg |
PICALM interacting mitotic regulator |
decreases expression |
ISO |
palbociclib results in decreased expression of PIMREG mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791
|
|
G |
Plk1 |
polo-like kinase 1 |
decreases expression multiple interactions |
ISO |
palbociclib results in decreased expression of PLK1 mRNA palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]] |
CTD |
PMID:20100483 PMID:22869556 |
|
NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400
|
|
G |
Pola2 |
DNA polymerase alpha 2, accessory subunit |
decreases expression |
ISO |
palbociclib results in decreased expression of POLA2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348
|
|
G |
Pole2 |
DNA polymerase epsilon 2, accessory subunit |
decreases expression |
ISO |
palbociclib results in decreased expression of POLE2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305
|
|
G |
Porcn |
porcupine O-acyltransferase |
increases expression |
ISO |
palbociclib results in increased expression of PORCN mRNA |
CTD |
PMID:22869556 |
|
NCBI chr X:14,285,864...14,298,481
Ensembl chr X:14,285,871...14,298,481
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of PRC1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765
|
|
G |
Prim1 |
DNA primase subunit 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of PRIM1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526
|
|
G |
Prr11 |
proline rich 11 |
decreases expression |
ISO |
palbociclib results in decreased expression of PRR11 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012
|
|
G |
Prss23 |
serine protease 23 |
increases expression |
ISO |
palbociclib results in increased expression of PRSS23 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091
|
|
G |
Psrc1 |
proline and serine rich coiled-coil 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of PSRC1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression |
ISO |
palbociclib results in decreased expression of PTTG1 mRNA |
CTD |
PMID:22869556 PMID:28620137 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RACGAP1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Rad51ap1 |
RAD51 associated protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RAD51AP1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524
|
|
G |
Ranbp1 |
RAN binding protein 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RANBP1 mRNA |
CTD |
PMID:28620137 |
|
NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
affects phosphorylation decreases expression increases response to substance multiple interactions affects response to substance decreases response to substance affects reaction increases phosphorylation decreases phosphorylation |
ISO |
palbociclib affects the phosphorylation of RB1 protein palbociclib results in decreased expression of RB1 mRNA; palbociclib results in decreased expression of RB1 protein RB1 protein results in increased susceptibility to palbociclib [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein RB1 protein affects the susceptibility to palbociclib BMS 754807 promotes the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib inhibits the reaction [bisphenol S results in increased phosphorylation of RB1 protein]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RB1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of RB1 protein] RB1 gene mutant form results in decreased susceptibility to palbociclib; RB1 mutant form results in decreased susceptibility to palbociclib RB1 protein affects the reaction palbociclib palbociclib results in increased phosphorylation of RB1 protein |
CTD |
PMID:15542782 PMID:16690963 PMID:17537993 PMID:19435910 PMID:19874578 PMID:20100483 PMID:20354191 PMID:20473330 PMID:20534551 PMID:21217777 PMID:21278246 PMID:21367843 PMID:21593195 PMID:21880723 PMID:22094256 PMID:22170262 PMID:22383795 PMID:22751436 PMID:22761470 PMID:22869556 PMID:23138228 PMID:23676220 PMID:23708653 PMID:24098593 PMID:24495407 PMID:24736461 PMID:24986516 PMID:25221644 PMID:26174628 PMID:26318986 PMID:26873845 PMID:28620137 PMID:30684532 More...
|
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
multiple interactions decreases expression |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of RBL1 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]; palbociclib promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RBL1 protein]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RBL1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein] palbociclib results in decreased expression of RBL1 mRNA; palbociclib results in decreased expression of RBL1 protein |
CTD |
PMID:20100483 PMID:20473330 |
|
NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions decreases phosphorylation |
ISO |
palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib results in decreased phosphorylation of and results in increased expression of RBL2 protein; palbociclib results in increased expression of and results in increased stability of RBL2 protein palbociclib results in decreased phosphorylation of RBL2 protein |
CTD |
PMID:20100483 PMID:20473330 PMID:22094256 PMID:26174628 |
|
NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572
|
|
G |
Rdh5 |
retinol dehydrogenase 5 |
increases expression |
ISO |
palbociclib results in increased expression of RDH5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558
|
|
G |
Rfc5 |
replication factor C subunit 5 |
decreases expression |
ISO |
palbociclib results in decreased expression of RFC5 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312
|
|
G |
Rps29 |
ribosomal protein S29 |
increases expression |
ISO |
palbociclib results in increased expression of RPS29 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:87,635,229...87,636,627
Ensembl chr 6:87,635,230...87,636,636
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
palbociclib promotes the reaction [BMS 754807 results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:24986516 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rrm1 |
ribonucleotide reductase catalytic subunit M1 |
decreases expression |
ISO |
palbociclib results in decreased expression of RRM1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
palbociclib results in decreased expression of RRM2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Sapcd2 |
suppressor APC domain containing 2 |
decreases expression |
ISO |
palbociclib results in decreased expression of SAPCD2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:8,186,089...8,195,119
Ensembl chr 3:8,187,266...8,192,546
|
|
G |
Senp3 |
SUMO specific peptidase 3 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein] |
CTD |
PMID:22094256 |
|
NCBI chr10:54,390,698...54,399,590
Ensembl chr10:54,390,694...54,399,593
|
|
G |
Serpine1 |
serpin family E member 1 |
increases expression |
ISO |
palbociclib results in increased expression of SERPINE1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Shox2 |
SHOX homeobox 2 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein] |
CTD |
PMID:22094256 |
|
NCBI chr 2:151,217,049...151,227,180
Ensembl chr 2:151,217,552...151,227,143
|
|
G |
Slc16a4 |
solute carrier family 16, member 4 |
increases expression |
ISO |
palbociclib results in increased expression of SLC16A4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117
|
|
G |
Smc4 |
structural maintenance of chromosomes 4 |
decreases expression |
ISO |
palbociclib results in decreased expression of SMC4 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions increases expression |
ISO |
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of SNAI2 protein] |
CTD |
PMID:22869556 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein] |
CTD |
PMID:21880723 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
palbociclib results in increased expression of SPARC mRNA |
CTD |
PMID:28620137 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spc24 |
SPC24 component of NDC80 kinetochore complex |
decreases expression |
ISO |
palbociclib results in decreased expression of SPC24 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:20,300,315...20,305,354
Ensembl chr 8:20,300,319...20,305,310
|
|
G |
Spc25 |
SPC25 component of NDC80 kinetochore complex |
decreases expression |
ISO |
palbociclib results in decreased expression of SPC25 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959
|
|
G |
Stil |
STIL, centriolar assembly protein |
decreases expression |
ISO |
palbociclib results in decreased expression of STIL mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:128,520,837...128,573,732
Ensembl chr 5:128,520,953...128,573,730
|
|
G |
Stmn1 |
stathmin 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of STMN1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Tacc3 |
transforming, acidic coiled-coil containing protein 3 |
decreases expression |
ISO |
palbociclib results in decreased expression of TACC3 mRNA |
CTD |
PMID:28620137 |
|
NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases activity |
ISO |
palbociclib results in increased activity of TGFB1 protein |
CTD |
PMID:22869556 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tk1 |
thymidine kinase 1 |
decreases expression |
ISO |
palbociclib analog results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 protein |
CTD |
PMID:15542782 PMID:22170262 PMID:22869556 |
|
NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920
|
|
G |
Tmpo |
thymopoietin |
decreases expression |
ISO |
palbociclib results in decreased expression of TMPO mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Top1 |
DNA topoisomerase I |
decreases expression |
ISO |
palbociclib results in decreased expression of TOP1 mRNA |
CTD |
PMID:24549232 |
|
NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression multiple interactions |
ISO |
palbociclib analog results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A protein palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]] |
CTD |
PMID:15542782 PMID:20948315 PMID:22751436 PMID:22869556 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
decreases response to substance |
ISO |
TP53 protein mutant form results in decreased susceptibility to palbociclib |
CTD |
PMID:21278246 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpx2 |
TPX2, microtubule nucleation factor |
decreases expression |
ISO |
palbociclib results in decreased expression of TPX2 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468
|
|
G |
Troap |
trophinin associated protein |
decreases expression |
ISO |
palbociclib results in decreased expression of TROAP mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 7:130,233,534...130,242,369
Ensembl chr 7:130,234,544...130,242,365
|
|
G |
Ttc14 |
tetratricopeptide repeat domain 14 |
increases expression |
ISO |
palbociclib results in increased expression of TTC14 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 2:116,653,543...116,665,072
Ensembl chr 2:116,653,595...116,664,158
|
|
G |
Ttk |
Ttk protein kinase |
decreases expression |
ISO |
palbociclib results in decreased expression of TTK mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Tubb4b |
tubulin, beta 4B class IVb |
decreases expression |
ISO |
palbociclib results in decreased expression of TUBB4B mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
decreases expression |
ISO |
palbociclib results in decreased expression of TUBB mRNA |
CTD |
PMID:22869556 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression |
ISO |
palbociclib results in decreased expression of TYMS mRNA; palbociclib results in decreased expression of TYMS protein |
CTD |
PMID:20948315 PMID:22869556 |
|
NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
decreases expression |
ISO |
palbociclib results in decreased expression of UBE2C mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Ube2t |
ubiquitin-conjugating enzyme E2T |
decreases expression |
ISO |
palbociclib results in decreased expression of UBE2T mRNA |
CTD |
PMID:22869556 |
|
NCBI chr13:46,403,352...46,413,854
Ensembl chr13:46,403,375...46,414,835
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
decreases expression |
ISO |
palbociclib results in decreased expression of UHRF1 mRNA |
CTD |
PMID:22869556 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Vim |
vimentin |
increases expression |
ISO |
palbociclib results in increased expression of VIM protein |
CTD |
PMID:22869556 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Zeb1 |
zinc finger E-box binding homeobox 1 |
multiple interactions |
ISO |
palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein] |
CTD |
PMID:22094256 |
|
NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214
|
|
G |
Zwint |
ZW10 interacting kinetochore protein |
decreases expression |
ISO |
palbociclib results in decreased expression of ZWINT mRNA |
CTD |
PMID:22869556 |
|
NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957
|
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
EXP |
roscovitine decreases expression of Ccng1 in rat brain injury lesions |
RGD |
PMID:18612315 |
RGD:151356935 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases activity |
EXP |
Roscovitine decreases activity of Cdk1 protein in oocytes |
RGD |
PMID:15695611 |
RGD:2301352 |
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
increases expression |
EXP |
roscovitine (seliciclib) increases expression of mRNA inhibiting the reaction [camptothecin increases kinase activity] in rat cerebellar granule neurons |
RGD |
PMID:19151707 |
RGD:10053571 |
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression |
EXP |
roscovitine (seliciclib) increases expression of mRNA inhibiting the reaction [camptothecin increases kinase activity] in rat cerebellar granule neurons |
RGD |
PMID:19151707 |
RGD:10053571 |
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|